Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Premaitha Health, Leica Biosystems, Mesa Biotech, and More

NEW YORK (360Dx) – Premaitha Health said that its CE-marked noninvasive prenatal Iona test has been validated for use on Thermo Fisher Scientific’s Ion S5 range of instruments. Its validation, completed in partnership with Thermo Fisher, could potentially broaden Premaitha’s laboratory customer base. With the validation, the Iona test presents a potential NIPT solution for use with the Ion S5 instrument's growing network of laboratories, Premaitha said.

Leica Biosystems and the Kuwait Ministry of Health, through its distributor Technical Services Supplies Trading & Contracting, have collaborated to make Leica’s digital pathology its standard of care. The partners said that the deal will create a nationwide pathology network powered by Aperio ePathology Solutions, linking eight hospitals and leveraging pathology expertise across Kuwait.

Mesa Biotech received ISO 13485:2003 certification, moving the firm a step closer to commercializing its Accula point-of-care system for infectious disease diagnostics in the US and European Union. ISO 13485:2003 specifies the quality requirements needed to demonstrate medical devices and related services meet customer and regulatory requirement. The firm said recently that it expects its platform will receive CE marking and be available for distribution in Europe this summer.   

Luminex said its board of directors declared a cash dividend for the second quarter of 2017 of $.06 per common share, payable on July 14 to holders of record on June 23.

Becton Dickinson said its board of directors declared a quarterly dividend of $.73 per common share, payable on June 30 to holders of record on June 9.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.